ALNY Alnylam Pharmaceuticals, Inc.
$226.79▼ -0.38%
Healthcare
Other
Volume 1.60M
Avg Volume (10D) 1.36M
Key Metrics & Fundamentals
Market Cap
$30.35B
P/E Ratio
38.2
Div Yield
0.00%
52W Range
197.81 - 484.61
% vs 50 MA
-5.14%
% vs 200 MA
-21.30%
RSI-14
44.6
MACD Histogram
+0.3400
Beta (1Y vs SPY)
0.42
Free Cash Flow
$292.04M
Gross Rev
$1.29B
Gross Profit
$992.50M
EBITDA
$273.76M
COGS
$298.45M
Operating Exp
$761.06M
Operating Income
$231.44M
EBIT
$231.44M
Pretax Income
$177.81M
Net Income
$164.49M
EPS (Diluted)
1.21
Price & Volume History
Loading chart…
Recent News
Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial
MarketBeat · Oct 26, 2026 1:03 PM ET
Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
Zacks · Oct 26, 2026 9:00 AM ET
Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?
Trefis · Oct 23, 2026 1:29 PM ET
Alnylam Pharmaceuticals Reports 60% to 64% Huntingtin Reduction in Brezosiran Trial
MT Newswires · Oct 23, 2026 4:35 AM ET
How Much Downside Is Left In Moderna Stock?
Trefis · Oct 23, 2026 4:00 AM ET
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease
Business Wire · Oct 23, 2026 3:45 AM ET
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks · Oct 22, 2026 9:00 AM ET
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Motley Fool · Oct 21, 2026 5:04 AM ET
Why Should You Think About Vertex Differently Now?
Trefis · Oct 20, 2026 8:56 PM ET
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?
Insider Monkey · Oct 20, 2026 1:33 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ALNY's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.